Johnson & Johnson Stock Surges 0.73% as FDA Approves Diabetes Therapy and Announces Logistics Partnership $1.41 Billion Volume Ranks 60th in Market Activity

, 2025, , ranking 60th in market activity. The stock's performance followed a series of regulatory updates and strategic announcements impacting its core healthcare divisions. A key development involved the FDA's conditional approval of a novel diabetes therapy under its accelerated review pathway, positioning the product for early market entry. Additionally, the company announced a partnership with a European logistics firm to streamline global supply chains for its over-the-counter pharmaceuticals, addressing recent distribution bottlenecks in key markets.

Analysts highlighted the stock's resilience amid sector-wide volatility, noting that Johnson's across medical devices, pharmaceuticals, and consumer health helped buffer against market downturns. Recent earnings calls had emphasized cost-cutting measures in its surgical division, . , signaling confidence in domestic market conditions despite broader economic uncertainties.

To run this back-test robustly I need to clarify a few practical details about how you’d like the strategy implemented: Trading universe—Do we use the full US equity universe (e.g., all common shares on NYSE + NASDAQ) or a specific subset such as Russell 3000 constituents? Weighting method—Equal-weight each of the 500 names, or weight by (say) dollar volume / market-cap? Pricing & execution assumptions—Enter at the same day’s close and exit at the next day’s close (T+1)? Any slippage / commission you want to include? Benchmark (optional)—Should I compare the strategy against SPY or another index? Please let me know, and I’ll build the back-test accordingly.